Clinical Applications & Treatments
    in Ginecology

    Clinical applications

    Vulvo-vaginal atrophy (postmenopausal and non-postmenopausal):
    → Treatment of thin, fragile, and hypoelastic mucosa, particularly at the level of the vaginal introitus; improves hydration, trophism, and tissue elasticity. Neoangiogenic effect.
    Vulvar lichen sclerosus:
    → Reduction of scar sclerosis and chronic itching through regeneration of connective tissue. Neoangiogenic effect.
    Scars and post-surgical outcomes:
    → Treatment of adhesions and fibrosis following episiotomy, Bartholin’s cysts, abscess incisions, and oncological procedures; improvement of local elasticity and sensitivity. Neoangiogenic effect.
    Vaginal dryness resistant to local therapies (including in reproductive age):
    → Restoration of the vaginal microenvironment and improvement of physiological lubrication. Neoangiogenic effect.
    Sexual dysfunctions related to tissue deficits (pain, hyposensitivity, loss of tone):
    → Sensory recovery, increased coital comfort, and improvement in sexual quality of life. Neoangiogenic effect.
    “Wide vagina” syndrome:
    → Enhancement of tone, mucosal thickness, and tissue support in the absence of pain but with reduced coital sensitivity. Neoangiogenic effect.
    Mild-to-moderate stress urinary incontinence:
    → Trophic support to periurethral tissues, improvement in tone and continence. Neoangiogenic effect.

    Role of mesenchymal Stem Cells (ADSCS)
    in Ginecology

    Adipose-derived mesenchymal stem cells (ADSCs) play a central role in gynecologic regenerative therapies due to their ability to:

    → modulate chronic inflammation,
    → promote soft tissue regeneration,
    → enhance neovascularization and tissue remodeling

    Vaginal mucosa:
    → ADSCs help restore mucosal trophism, hydration, and thickness, improving conditions such as vulvovaginal atrophy and persistent dryness.

    Perineal and vulvar tissues:
    → They promote tissue repair in cases of post-episiotomy scars, lacerations, or vulvar surgery outcomes.

    Chronically inflamed vulvar tissues (e.g., lichen sclerosus):
    → ADSCs reduce inflammation and fibrosis, improving local elasticity and comfort.

    Urogenital area (urethra/periurethral tissues):
    → They support connective tissue regeneration and tone improvement in mild to moderate stress urinary incontinence.

    Clinical effects

    Anti-inflammatory Effect
    → ADSCs reduce chronic inflammation in vulvovaginal tissues through the secretion of anti-inflammatory cytokines (IL-10, TGF-β).
    → Decreased swelling, itching, and local pain.
    → Improvement of symptoms in chronic inflammatory conditions such as lichen sclerosus.

    Regenerative Effect
    They stimulate regeneration of fibroblasts, keratinocytes, and endothelial cells.
    → Restoration of mucosal structure and elasticity.
    → Improved quality of atrophic or scarred tissues.
    → Restoration of microcirculation and tissue trophism.

    Analgesic Effect
    Their combined anti-inflammatory and trophic actions reduce pain, especially in cases of vaginal dryness, postpartum or surgical scarring, and lichen.
    → Reduced need for topical anesthetics or local hormonal therapies.

    Immunomodulatory Effect
    ADSCs modulate the local immune response, attenuating autoimmune and fibrotic processes.
    → Useful in chronic immune-mediated vulvar diseases.

    Functional Improvement and Quality of Life
    → Increased lubrication, elasticity, and tissue sensitivity.
    → Enhanced comfort during sexual intercourse and overall uro-genital wellbeing.

    Clinical Applications of
    Intragraft Fat® in Gynecology